Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1985 Feb;27(2):192–196. doi: 10.1128/aac.27.2.192

Single-dose pharmacokinetics of ceftriaxone in healthy Chinese adults.

H H Zhou, Y P Chan, K Arnold, M Sun
PMCID: PMC176236  PMID: 3985603

Abstract

The pharmacokinetics of ceftriaxone were investigated in six healthy mainland Chinese adults (four males and two females). A single 1.0-g dose was administered intravenously or intramuscularly in a two-way crossover design. Plasma and saliva samples were collected on 11 occasions between 0 and 36 h after dosing. Ceftriaxone was not detected in any saliva samples. The mean volume of distribution and mean elimination half-life of ceftriaxone in plasma were 8.5 liters and 8.1 h, respectively. The mean total body clearance after intravenous administration was 0.68 liter/h. The mean Tmax and Cmax after intramuscular injection were 1.4 h and 131 micrograms/ml, respectively. The area under the plasma concentration-time curves after intravenous and intramuscular administrations were 1,507 and 1,493 micrograms X h/ml, respectively. The bioavailability for a 1.0-g intramuscular dose of ceftriaxone was calculated to be 100%. These pharmacokinetic parameters for ceftriaxone in healthy Chinese adults were very similar to those previously reported in the literature. Thus, ceftriaxone may be administered to treat Chinese patients without any major modification in the standard dosing regimen.

Full text

PDF
192

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angehrn P., Probst P. J., Reiner R., Then R. L. Ro 13-9904, a long-acting broad-spectrum cephalosporin: in vitro and in vivo studies. Antimicrob Agents Chemother. 1980 Dec;18(6):913–921. doi: 10.1128/aac.18.6.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Branch R. A., Salih S. Y., Homeida M. Racial differences in drug metabolizing ability: a study with antipyrine in the Sudan. Clin Pharmacol Ther. 1978 Sep;24(3):283–286. doi: 10.1002/cpt1978243283. [DOI] [PubMed] [Google Scholar]
  3. Delsignore R., Baroni C. M., Crotti G., Mineo F., Butturini U., Ascalone V., Cisternino M. Absolute bioavailability of ceftriaxone after intramuscular administration to healthy volunteers. Chemotherapy. 1983;29(3):157–162. doi: 10.1159/000238191. [DOI] [PubMed] [Google Scholar]
  4. Idle J. R., Smith R. L. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance. Drug Metab Rev. 1979;9(2):301–317. doi: 10.3109/03602537908993896. [DOI] [PubMed] [Google Scholar]
  5. Kalow W., Tang B. K., Kadar D., Endrenyi L., Chan F. Y. A method for studying drug metabolism in populations: racial differences in amobarbital metabolism. Clin Pharmacol Ther. 1979 Dec;26(6):766–776. doi: 10.1002/cpt1979266766. [DOI] [PubMed] [Google Scholar]
  6. Lubin A. H., Garry P. J., Owen G. M. Sex and population differences in the incidence of a plasma cholinesterase variant. Science. 1971 Jul 9;173(3992):161–164. doi: 10.1126/science.173.3992.161. [DOI] [PubMed] [Google Scholar]
  7. McNamara P. J., Stoeckel K., Ziegler W. H. Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur J Clin Pharmacol. 1982;22(1):71–75. doi: 10.1007/BF00606428. [DOI] [PubMed] [Google Scholar]
  8. Meyers B. R., Srulevitch E. S., Jacobson J., Hirschman S. Z. Crossover study of the pharmacokinetics of ceftriaxone administered intravenously or intramuscularly to healthy volunteers. Antimicrob Agents Chemother. 1983 Nov;24(5):812–814. doi: 10.1128/aac.24.5.812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Patel I. H., Chen S., Parsonnet M., Hackman M. R., Brooks M. A., Konikoff J., Kaplan S. A. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother. 1981 Nov;20(5):634–641. doi: 10.1128/aac.20.5.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Patel I. H., Miller K., Weinfeld R., Spicehandler J. Multiple intravenous dose pharmacokinetics of ceftriaxone in man. Chemotherapy. 1981;27 (Suppl 1):47–56. doi: 10.1159/000238029. [DOI] [PubMed] [Google Scholar]
  11. Patel I. H., Weinfeld R. E., Konikoff J., Parsonnet M. Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. Antimicrob Agents Chemother. 1982 Jun;21(6):957–962. doi: 10.1128/aac.21.6.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pickup M. E., Bird H. A., Lowe J. R., Lees L., Wright V. A pharmacokinetic and tolerance study of Ro13-9904, a new cephalosporin antibiotic. Br J Clin Pharmacol. 1981 Aug;12(2):111–115. doi: 10.1111/j.1365-2125.1981.tb01188.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ritschel W. A., Tompson G. A. Monitoring of drug concentrations in saliva: a non-invasive pharmacokinetic procedure. Methods Find Exp Clin Pharmacol. 1983 Oct;5(8):511–525. [PubMed] [Google Scholar]
  14. Seddon M., Wise R., Gillett A. P., Livingston R. Pharmacokinetics of Ro 13-9904, a broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1980 Aug;18(2):240–242. doi: 10.1128/aac.18.2.240. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Spector R., Choudhury A. K., Chiang C. K., Goldberg M. J., Ghoneim M. M. Diphenhydramine in Orientals and Caucasians. Clin Pharmacol Ther. 1980 Aug;28(2):229–234. doi: 10.1038/clpt.1980.155. [DOI] [PubMed] [Google Scholar]
  16. Stamatoyannopoulos G., Chen S. H., Fukui M. Liver alcohol dehydrogenase in Japanese: high population frequency of atypical form and its possible role in alcohol sensitivity. Am J Hum Genet. 1975 Nov;27(6):789–796. [PMC free article] [PubMed] [Google Scholar]
  17. Stoeckel K., McNamara P. J., Brandt R., Plozza-Nottebrock H., Ziegler W. H. Effects of concentration-dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther. 1981 May;29(5):650–657. doi: 10.1038/clpt.1981.90. [DOI] [PubMed] [Google Scholar]
  18. Stoeckel K. Pharmacokinetics of Rocephin, a highly active new cephalosporin with an exceptionally long biological half-life. Chemotherapy. 1981;27 (Suppl 1):42–46. doi: 10.1159/000238028. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES